While early-stage cancer detection using liquid biopsy remains challenging, it can complement tissue testing by identifying actionable mutations like KRAS and EGFR even in non-metastatic and locally advanced stages, guiding personalized treatment in a timely manner. The gene discussed is EGFR; the disease is cancer.